HPV16-E6-DNA对宫颈癌预后价值分析

doi:10.3969/j.issn.1006-6233.2017.12.003

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1402 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the prognostic value of HPV16-E6-DNA in cervical cancer. Methods: A retrospective analysis of our hospital in January 2014 ~2017 year in March 72 cases of cervical cancer patients with clinical data, blood tests, using fluorescence quantitative (PCR) technique for detection of HPV16-E6-DNA virus load, according to the test results of the patients were divided into two groups, namely low load and high load group, using fluorescence quantitative (RT-PCR) determination of cervix cancer tissue HPV16-E6-DNA viral load, using Kaplan-Meier to calculate the survival rates of the two groups, using the factor Cox regression analysis in patients with 5-year-survival rates. Results: The expression levels of HPV16-E6-DNA viral load in patients with cervical cancer were related to age, FIGO stage and lymph node metastasis (P<0.05); The 1, 3 and 5 year survival rates of the patients in the low load group were 95.66%, 89.31% and 74.30% respectively; The 1, 3 and 5 year survival rates of the patients in the high load group were 89.10%, 62.61% and 51.36% respectively; The survival rate of patients in the low load group was significantly higher than that of high load group, the difference was statistically significant (P<0.05); Cox regression analysis showed that HPV16-E6-DNA viral load and lymph node metastasis were the important factors affecting the prognosis of patients with cervical cancer (P<0.05). Conclusion: HPV16-E6-DNA virus is an important predictor of the prognosis of cervical cancer patients. It is an important factor in the prognosis of cervical cancer after radical resection. It is also an independent factor in the survival rate of cervical cancer after radical operation.

Key words： Cervical cancer Patients HPV16-E6-DNA Viral load

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Yingxing
	HUANG Yong

Cite this article:

CHENG Yingxing,HUANG Yong. The Prognostic Value of HPV16-E6-DNA for Cervical Cancer[J]. HeBei Med, 2017, 23(12): 1944-1947.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2017.12.003 OR http://www.hbyxzzs.cn/EN/Y2017/V23/I12/1944

[1] 帕提曼,米吉提,唐努尔.HPV16-E6-DNA病毒载量对预测宫颈癌患者生存状况的影响[J].癌症进展,2016,14(6):548~550.
[2] 宋晓玲,蔡红兵.HPV16-E6-DNA对宫颈癌预后预测价值分析[J].中华肿瘤防治杂志,2015,22(06):416~420.
[3] 王琳,隋霜,玛依努尔·尼牙孜,等.HPV16E6基因和蛋白水平与维汉宫颈病变进展的关系研究[J].现代妇产科进展,2015(8):594~597.
[4] 曹泽毅.妇科常见肿瘤诊治指南[M].人民卫生出版社,2010.
[5] Mazumder D, Singh R K, Mitra S, et al. Genetic and epigenetic changes of HPV16 in cervical cancer differentially regulate E6/E7 expression and associate with disease progression[J].Gynecologic Oncology, 2011, 123(3):597~604.
[6] 覃小敏,李琳,黄艳丽,等.中老年宫颈癌患者预后相关影响因素的分析[J].癌症进展,2015(3):346~349.
[7] 胡尚英,赵方辉,马俊飞,等.轻度宫颈上皮内瘤变预后及其与人乳头状瘤病毒关系的前瞻性队列研究[J].中华预防医学杂志,2014,48(5):361~365.
[8] 李小华,王俊然,冬国友,等.高危型人乳头瘤样病毒DNA检测在宫颈癌早期筛查中的作用[J].重庆医学,2013,42(8):939~940.
[9] 岑尧,张翠英,张雅丽,等.中国女性人乳头瘤病毒感染状况及高危型别分布的Meta分析[J].癌症进展,2013,11(1):75~81.
[10] 陆晓楣,李晶,刘畅浩,等.年轻宫颈癌患者的病理特点和预后分析[J].中国妇产科临床杂志,2011,12(01):10~13.
[11] 严鸣,张彦娜,何洁华,等.淋巴脉管间隙浸润对早期宫颈鳞癌预后的影响[J].癌症,2010,29(4):468~474.
[12] 曾四元,梁美蓉,李隆玉,等.血清SCCA水平及盆腔淋巴结HPV16/18感染状况与宫颈鳞癌患者预后的关系[J].基础医学与临床,2012,32(10):1167~1170.
[13] 安振,万艳平.HPV16 E6蛋白在宫颈癌中的作用研究进展[J].微生物学免疫学进展,2015,43(3):42~46.